CL2017002614A1 - Método para la purificación de proteínas - Google Patents

Método para la purificación de proteínas

Info

Publication number
CL2017002614A1
CL2017002614A1 CL2017002614A CL2017002614A CL2017002614A1 CL 2017002614 A1 CL2017002614 A1 CL 2017002614A1 CL 2017002614 A CL2017002614 A CL 2017002614A CL 2017002614 A CL2017002614 A CL 2017002614A CL 2017002614 A1 CL2017002614 A1 CL 2017002614A1
Authority
CL
Chile
Prior art keywords
protein purification
domain
provides
present
antibody
Prior art date
Application number
CL2017002614A
Other languages
English (en)
Inventor
Sam Philip Heywood
Gavin Barry Wild
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2017002614A1 publication Critical patent/CL2017002614A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>La presente invención proporciona un método para recuperar un anticuerpo humano que contiene un dominio VH3 en forma de monómeros. En particular, la presente invención proporciona un nuevo método que permite la recuperación de anticuerpos humanos que contienen el dominio V1-13 en forma de menómeros de una mezcla que contiene formas monoméricas y multiméricas del anticuerpo</p>
CL2017002614A 2015-04-22 2017-10-16 Método para la purificación de proteínas CL2017002614A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1506868.7A GB201506868D0 (en) 2015-04-22 2015-04-22 Method for protein purification

Publications (1)

Publication Number Publication Date
CL2017002614A1 true CL2017002614A1 (es) 2018-04-27

Family

ID=53299017

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002614A CL2017002614A1 (es) 2015-04-22 2017-10-16 Método para la purificación de proteínas

Country Status (19)

Country Link
US (2) US10927164B2 (es)
EP (1) EP3286205A1 (es)
JP (2) JP6866300B2 (es)
KR (1) KR102675400B1 (es)
CN (1) CN107636012B (es)
AR (1) AR104358A1 (es)
AU (1) AU2016251223B2 (es)
BR (1) BR112017022073A2 (es)
CA (1) CA2983057A1 (es)
CL (1) CL2017002614A1 (es)
CO (1) CO2017010631A2 (es)
EA (1) EA201792328A1 (es)
GB (1) GB201506868D0 (es)
IL (1) IL254883B (es)
MA (1) MA41941A (es)
MX (1) MX2017013333A (es)
MY (1) MY189854A (es)
SG (1) SG11201708256YA (es)
WO (1) WO2016169992A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013081540A1 (en) * 2011-11-30 2013-06-06 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
CN108085358A (zh) * 2018-02-08 2018-05-29 保定冀中药业有限公司 一种犬细小病毒单克隆抗体IgG2b-Fab片段的制备方法
BR112021023542A2 (pt) * 2019-08-02 2022-03-22 UCB Biopharma SRL Métodos para purificar anticorpos
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
CN115003695A (zh) * 2019-12-26 2022-09-02 爱必乐生物公司 一种使用蛋白a亲和层析法纯化生物活性肽的方法
GB202109246D0 (en) * 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
JP2002544237A (ja) * 1999-05-15 2002-12-24 ユニバーシティ オブ カリフォルニア，サン ディエゴ 望ましい活性を有するプロテインａに基づく結合ドメイン
AU2002246737B2 (en) * 2000-12-29 2007-03-01 Savient Pharmaceuticals, Inc. Specific human antibodies for selective cancer therapy
EP1614693A4 (en) * 2003-03-31 2006-07-19 Kirin Brewery PURIFICATION OF A HUMAN MONOCLONAL ANTIBODY AND A HUMAN POLYCLONAL ANTIBODY
SG2013061528A (en) 2008-08-14 2015-03-30 Merck Sharp & Dohme Methods for purifying antibodies using protein a affinity chromatography
SG173620A1 (en) * 2009-02-17 2011-09-29 Ucb Pharma Sa Antibody molecules having specificity for human ox40
WO2012059308A1 (en) * 2010-11-01 2012-05-10 Dsm Ip Assets B.V. Single unit ion exchange chromatography antibody purification
JP2014502272A (ja) 2010-11-29 2014-01-30 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ アフィニティークロマトグラフィーマトリックス
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
PT2776466T (pt) 2011-11-11 2017-11-30 Ucb Biopharma Sprl Anticorpos de ligação a albumina e seus fragmentos de ligação
CN104105711B (zh) * 2012-02-10 2018-11-30 弗·哈夫曼-拉罗切有限公司 单链抗体及其他异多聚体
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
CA2929256C (en) * 2013-11-04 2022-04-26 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
MA41941A (fr) 2018-02-28
CO2017010631A2 (es) 2018-01-05
IL254883A0 (en) 2017-12-31
JP2018520089A (ja) 2018-07-26
AU2016251223B2 (en) 2021-12-09
CN107636012B (zh) 2022-08-02
BR112017022073A2 (pt) 2018-08-14
AR104358A1 (es) 2017-07-12
AU2016251223A1 (en) 2017-10-26
KR20170139131A (ko) 2017-12-18
JP6866300B2 (ja) 2021-04-28
CA2983057A1 (en) 2016-10-27
MY189854A (en) 2022-03-14
EA201792328A1 (ru) 2018-05-31
US10927164B2 (en) 2021-02-23
IL254883B (en) 2021-09-30
KR102675400B1 (ko) 2024-06-13
WO2016169992A1 (en) 2016-10-27
CN107636012A (zh) 2018-01-26
US20210171609A1 (en) 2021-06-10
JP2021066734A (ja) 2021-04-30
SG11201708256YA (en) 2017-11-29
US20180100007A1 (en) 2018-04-12
EP3286205A1 (en) 2018-02-28
MX2017013333A (es) 2018-02-19
GB201506868D0 (en) 2015-06-03

Similar Documents

Publication Publication Date Title
CL2017002614A1 (es) Método para la purificación de proteínas
EA202092435A2 (ru) Моноклональные антитела против bcma
CL2018000502A1 (es) Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer.
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
CR20170026A (es) Anticuerpos anti-tau humanizados
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201691991A1 (ru) Мультиспецифические антитела
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
EA201691974A1 (ru) Антитела против ox40 и способы их применения
PH12016500940A1 (en) HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
CO2020002060A2 (es) Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
CU24556B1 (es) Anticuerpos anti-basigin humanizados
CL2017000912A1 (es) Anticuerpos que se unen a ccr6 y sus usos
DOP2016000202A (es) Proteínas de fusión uti
EA201792527A1 (ru) Лечение зуда
EA201792492A1 (ru) Aml-антигены и их применение
AR110569A1 (es) ANTICUERPOS MONOCLONALES ANTI-a-SINUCLEÍNA PARA PREVENIR LA AGREGACIÓN DE TAU
TH1601003449A (th) Pd-1 แอนติบอดี ชิ้นส่วนที่จับกับแอนติเจนของแอนติบอดีนั้น และการใช้แอนติบอดีนั้นทางการแพทย์
TH1601003749A (th) แอนทิบอดีชนิดโมโนคลอนัลที่ทำให้เป็นกลาง แอนทิ-il-33 ของมนุษย์
TH1601000764A (th) แอนติบอดีตามตัวยับยั้งพลาสมิโนเจนแอคติเวเตอร์-1 (pai-1) และการใช้ของสิ่งนั้น